SCHEMBL25008693

SCHEMBL25008693

CC(=O)NCCc1c[nH]c2c(C)ccc(O)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 4/20 0.52
▸ BLM P54132 4/20 0.52
▸ TSHR P16473 2/20 0.52
▸ LMNA P02545 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ PKM P14618 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ MTNR1A P48039 15/20 0.51
▸ MTNR1B P49286 14/20 0.51
▸ KDM4E B2RXH2 5/20 0.49
▸ HPGD P15428 5/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ CYP3A4 P08684 3/20 0.49
▸ CYP2D6 P10635 3/20 0.49
▸ NOTUM Q6P988 3/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ IDO1 P14902 1/20 0.49
▸ SPR P35270 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25028193 0.83 HTR2A (0.60) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL25029871 0.81 HTR2A (0.48) KMT2AMTNR1AMTNR1BMAPTMPO
SCHEMBL25008591 0.78 MTNR1A (0.59) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL31543651 0.78 CYP1A2 (0.59) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL26451459 0.77 MTNR1A (0.56) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL25001887 0.77 MTNR1A (0.56) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL6920054 0.77 MTNR1A (0.70) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL21333752 0.77 HTR2A (0.72) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL13644764 0.77 CYP1A2 (0.60) CYP1A2BLMTSHRLMNAMEN1
SCHEMBL26202274 0.76 MTNR1A (0.46) CYP1A2BLMTSHRLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250100967-A1 HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING Enveric Biosciences Canada Inc. (CA) 2025-03-27 — — US disclosed
US-12187679-B2 Hydroxylated psilocybin derivatives and methods of using Enveric Biosciences Canada Inc. (CA) 2025-01-07 — — US disclosed
US-20230043896-A1 HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING MAGICMED INDUSTRIES INC. (CA) 2023-02-09 — — US disclosed
US-20230043896-A1 HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING MAGICMED INDUSTRIES INC. (CA) 2023-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100967-A1 HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING HTR1B, HTR2B, CYP8B1 CYP1A2 42/4885BLM 4456/4885TSHR 4010/4885
US-20230043896-A1 HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING HTR1B, HTR2B, CYP8B1 CYP1A2 42/4885BLM 4456/4885TSHR 4010/4885
US-12187679-B2 Hydroxylated psilocybin derivatives and methods of using HTR1B, HTR2B, CYP8B1 CYP1A2 42/4885BLM 4456/4885TSHR 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback